MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$2,929,000
EPS
-$0.32
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
0
-
65,000*
0
Research and development
584,000
1,204,000
1,631,000*
1,959,000
General and administrative
3,408,000
3,738,000
2,720,000*
2,455,000
Total operating expenses
3,992,000
4,942,000
4,351,000*
4,414,000
Operating loss
-3,992,000
-4,942,000
-4,286,000*
-4,414,000
Investment income, net
79,000
120,000
207,500*
183,000
Other income (expense), net
984,000
-54,000
-107,500*
-18,000
Total other income
1,063,000
66,000
100,000*
165,000
Net loss before benefit from income taxes and noncontrolling interests
-2,929,000
-4,876,000
-4,186,000*
-4,249,000
Benefit from income taxes
0
-387,000
-962,000*
0
Net loss
-2,929,000
-4,489,000
-3,224,000*
-4,249,000
Less - net income (loss) attributable to noncontrolling interests
0
0
0*
0
Net loss attributable to lisata therapeutics, inc. common stockholders
-2,929,000
-4,489,000
-3,224,000
-4,249,000
Basic EPS
-0.32
-0.5
-0.37
-0.49
Diluted EPS
-0.32
-0.5
-0.37
-0.49
Basic Average Shares
9,106,000
9,006,000
8,718,000
8,738,000
Diluted Average Shares
9,106,000
9,006,000
8,718,000
8,738,000
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to lisata...
-$2,929,000
(37.13%↑ Y/Y)
Net loss
-$2,929,000
(37.13%↑ Y/Y)
Other income
(expense), net
$984,000
(14157.14%↑ Y/Y)
Investment income, net
$79,000
(-63.43%↓ Y/Y)
Net loss before
benefit from income...
-$2,929,000
(37.13%↑ Y/Y)
Total other income
$1,063,000
(408.61%↑ Y/Y)
Operating loss
-$3,992,000
(18.00%↑ Y/Y)
Total operating
expenses
$3,992,000
(-19.16%↓ Y/Y)
General and
administrative
$3,408,000
(26.93%↑ Y/Y)
Research and development
$584,000
(-74.08%↓ Y/Y)
Buy us a coffee
LISATA THERAPEUTICS, INC. (LSTA)
LISATA THERAPEUTICS, INC. (LSTA)